Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacira Biosciences, Inc. on September 26, 2024. The filing addresses Item 5.02 regarding the departure of a senior officer and the appointment of an interim successor.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on executive personnel changes and compensation arrangements.
Material Changes
- Departure of CFO: Charles A. Reinhart, III, Chief Financial Officer, will depart the Company effective September 30, 2024. He will serve as a consultant for nine months following his departure.
- Appointment of Interim CFO: Lauren Riker, currently Senior Vice President of Finance and principal accounting officer, was appointed Interim Chief Financial Officer effective October 1, 2024.
- Compensation Adjustment: Ms. Riker will receive a one-time $75,000 bonus in connection with her appointment. Her base salary ($374,700) and annual incentive targets remain unchanged.
Outlook, Risks, and Contingencies
The filing details specific severance and change-of-control provisions for Ms. Riker:
- Termination without Cause/Good Reason: Entitles Ms. Riker to nine months of salary continuation, 12 months of health insurance, and accelerated vesting of options that would have vested during the nine-month period.
- Change of Control: If termination occurs within 30 days prior to or 12 months following a change of control, Ms. Riker is entitled to 12 months of salary continuation, a full target bonus, 12 months of health insurance, and immediate vesting of all outstanding unvested options.
- Repayment Clause: The $75,000 appointment bonus is repayable if Ms. Riker is terminated for "cause" or resigns without "good reason" within one year of payment.
Investor Verification Checklist
- Verify the exact departure date of Charles A. Reinhart, III (September 30, 2024).
- Confirm the effective date of Lauren Riker's interim CFO role (October 1, 2024).
- Review the full Employment Agreement (to be filed as an exhibit to the Q3 2024 Form 10-Q) for complete definitions of "cause" and "good reason."
- Monitor the search for a permanent CFO successor, as Ms. Riker's role is interim.